報價延遲最少15分鐘:2025/03/28 08:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.45 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.18/-3.20
|
|
企業價值
193.15M
|
| 資產負債 |
|
每股賬面淨值
7.66
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |